These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7995015)

  • 1. Biochemical actions of l-deprenyl (selegiline).
    Lange KW; Riederer P; Youdim MB
    Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 2):734-41. PubMed ID: 7995015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular pharmacology of L-deprenyl.
    Gerlach M; Riederer P; Youdim MB
    Eur J Pharmacol; 1992 Jun; 226(2):97-108. PubMed ID: 1639115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline.
    Gerlach M; Desser H; Youdim MB; Riederer P
    J Neural Transm Suppl; 1996; 48():7-21. PubMed ID: 8988458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (-)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system.
    Knoll J
    J Am Geriatr Soc; 1992 Aug; 40(8):839-47. PubMed ID: 1634730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes.
    Knoll J
    Biomed Pharmacother; 1995; 49(4):187-95. PubMed ID: 7669938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological actions of l-deprenyl (selegiline) and other selective monoamine oxidase B inhibitors.
    Youdim MB; Finberg JP
    Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 2):725-33. PubMed ID: 7995014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline).
    Wu RM; Mohanakumar KP; Murphy DL; Chiueh CC
    Ann N Y Acad Sci; 1994 Nov; 738():214-21. PubMed ID: 7832430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
    Magyar K; Szende B
    Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is selegiline neuroprotective in Parkinson's disease?
    Gerlach M; Youdim MB; Riederer P
    J Neural Transm Suppl; 1994; 41():177-88. PubMed ID: 7931225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
    Muralikrishnan D; Samantaray S; Mohanakumar KP
    Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.
    Nagatsu T; Sawada M
    J Neural Transm Suppl; 2006; (71):53-65. PubMed ID: 17447416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
    Youdim MB
    J Neural Transm Suppl; 1986; 22():91-105. PubMed ID: 3097263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacology of selegiline.
    Magyar K
    Int Rev Neurobiol; 2011; 100():65-84. PubMed ID: 21971003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deprenyl (selegiline): the history of its development and pharmacological action.
    Knoll J
    Acta Neurol Scand Suppl; 1983; 95():57-80. PubMed ID: 6428148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of selegiline.
    Gerlach M; Youdim MB; Riederer P
    Neurology; 1996 Dec; 47(6 Suppl 3):S137-45. PubMed ID: 8959982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-Methyl, N-propynyl-2-phenylethylamine (MPPE), a Selegiline Analog, Attenuates MPTP-induced Dopaminergic Toxicity with Guaranteed Behavioral Safety: Involvement of Inhibitions of Mitochondrial Oxidative Burdens and p53 Gene-elicited Pro-apoptotic Change.
    Shin EJ; Nam Y; Lee JW; Nguyen PT; Yoo JE; Tran TV; Jeong JH; Jang CG; Oh YJ; Youdim MBH; Lee PH; Nabeshima T; Kim HC
    Mol Neurobiol; 2016 Nov; 53(9):6251-6269. PubMed ID: 26563498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans: a personal view.
    Knoll J
    Pharmacol Toxicol; 1992 May; 70(5 Pt 1):317-21. PubMed ID: 1608919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl].
    Yasar S; Justinova Z; Lee SH; Stefanski R; Goldberg SR; Tanda G
    J Pharmacol Exp Ther; 2006 Apr; 317(1):387-94. PubMed ID: 16352699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.